Influence of genetic modification on toxicities of Methotrexate in children with Leukemia
Not Applicable
- Conditions
- Health Condition 1: C910- Acute lymphoblastic leukemia [ALL]
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Pediatric patients diagnosed with Acute Lymphoblastic Leukemia
2. Both male and female patients between the age group of 0 -18 years
3. Patients who are categorized as high-risk, intermediate-risk, and relapse based on the protocol
4. Patients who are being prescribed Intravenous (I.V) Methotrexate (500mg/m2-5gm/m2)
Exclusion Criteria
1. Patients with other types of malignancies
2. Patients who are being prescribed oral Methotrexate
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The study will predict the genetic variant gene responsible for the development of methotrexate-induced toxicity in ALL patients, which will be useful in tailoring the doses of Methotrexate for this population.Timepoint: After 24 hrs of methotrexate administration genetic analysis will be carried out
- Secondary Outcome Measures
Name Time Method Serum concentration leading to Methotrexate induced toxicities will be identifiedTimepoint: Patients serum concentration will be estimated at baseline, after 24 and 48 hrs after Methotrexate administration